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Univerzita Karlova v Praze 
Farmaceutická fakulta v Hradci Hrálové 
Katedra biochemických věd 
Kandidát:  Lucie Koubková 
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obsažených v biotransformované soji 
 
Rakovina prsu patří u žen mezi nejčastěji diagnostikované nádory. Přibližně 
60% nádorů prsu je tzv. hormon dependentní, mající na svém povrchu estrogenní 
receptory a vyžadující estrogeny ke svému růstu. Estrogeny jsou schopné podporovat 
transkripci genů účastnících se buněčné proliferace. Aromatáza je enzym katalyzující 
poslední krok biosyntézy estrogenů a její inhibice je považována za důležitý cíl v léčbě 
na estrogenu závislých nádorů prsu. Sója je zdrojem tzv. fytoestrogenů jako jsou 
genistein a daidzein. O těchto látkách se předpokládá, že by mohly být účinné 
v prevenci karcinomu prsu, avšak mechanismus jejich působení není plně pochopen. 
Tato práce je zaměřena na zhodnocení efektu extraktu sóji obsahující genistein 
a daidzein na aktivitu výše zmíněného enzymu. Výsledky ukázaly, že tento extrakt 
inhibuje aromatázu na dávce závislým způsobem, jednak v pokusech s placentálními 
mikrozomy, tak i v případě buněčné linie MCF-7aro. V pokusech s placentálními 
mikrozomy bylo rovněž prokázáno, že biotransformace extraktu sóji houbou 
Aspergillus awamori neměla žádný vliv na kapacitu indukce inhibice aromatázy. 
U buněčné linie MCF-7aro byla pozorována redukce proliferace a morfologické změny 
buněk v závislosti na dávce extraktu po 48-ti hodinové inkubaci. Extrakt sóji se zdá být 
slibným a účinným prostředkem v inhibici aromatázy. Avšak další studie jsou 
vyžadovány k detailnějšímu pochopení mechanismu inhibice aromatázy a objasnění, 
které látky jsou skutečně zodpovědné za inhibiční efekt. 
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Faculty of Pharmacy in Hradec Kralove 
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Title of diploma thesis:  Evaluation of anti-aromatase activity of isoflavones from 
biotransformed soya 
Breast cancer belongs to the most frequently diagnosed cancers in women. 
Approximately 60% of breast cancer is hormone-dependent containing estrogen 
receptors and requiring estrogen for tumour growth. Estrogens are able to promote 
transcription of genes involved in cell proliferation. Aromatase is responsible for the 
final step of estrogen biosynthesis and its inhibition has been considered as an important 
target for the treatment of estrogen-dependent breast cancer. Soya is a source of 
phytoestrogens, such as genistein and daidzein, which are thought to be effective in 
breast cancer prevention. However, the mechanisms associated with this effect are not 
fully understood.  In this study we evaluated the effects of a soya extract containing 
genistein and daidzein on aromatase activity. Our results demonstrated that this extract 
had the ability to inhibit aromatase in a dose-dependent manner in placental microsomes 
and also in the MCF-7aro breast cancer cell line. It was also shown that, in the placental 
microsomes, the biotransformation by fungi Aspergillus awamori did not alter the 
capacity to induce aromatase inhibition. In this cell line it was also observed a dose 
dependent reduction in cell proliferation and morphological alterations after 48 hours of 
treatment. This biotransformed extract seems to be quite potent and a promising agent 
to induce  aromatase inhibition, but further studies are required to better  understand the 
mechanism of aromatase inhibition by soya contents and elucidate what kind of 
compounds are exactly responsible for the inhibitory effect. 
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1. INTRODUCTION 
1.1 Breast cancer  
Cancer is the second leading cause of death after the coronary diseases.  There 
are 3.2 million diagnosed cases of cancer every year in Europe (47% occurring in 
women, 53% in men) and more than 1.7 million deaths from cancer (44% in women, 
56% in men) (Ferlay et al., 2007). There is a strong association between cancer risk and 
age. Due to the aging of the European population these numbers are probably going to 
increase. It is estimated that by 2015 there will be a 22% increase in the population 
aged >65 years and a 50% increase in the number of persons aged >80 years old  (Boyle 
and Ferlay, 2005). In 2006 the most common incident cancer was the breast cancer, 
followed by colorectal and lung cancer.  
Breast cancer belongs to the most frequently diagnosed cancers in women. 
World Health Organization estimates that breast cancer affects one out of every sixteen 
women in Europe during their lifetime [1]. Breast cancer incidence varied in Europe 
with lowest rates in Central Europe, Croatia and Slovenia (41 to 64 per 100,000) and 
highest rates in the Netherlands and Italy (91 per 100,000) (Karim-Kos et al., 2008).  
In Czech Republic according to the Institute of Health Information and Statistics 
there were reported 5884 new cases of breast cancer in 2006, which represents almost 
17% of  all oncological diseases in women. Although the treatment of breast cancer 
especially in the very early stages is successful (almost 71% of cases of stage I and II) it 
remains the most common malignant neoplasm in women leading to death in Czech 
Republic (figure 1).  
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In the long term the mortality rates has slightly decreased. This reduction is due 
to the screening programs, which reveal the cancer in the beginning stage, due to better 
access to health care and also due to new approaches in breast cancer treatment. In 
addition, the breast cancer incidence has been attributed to the lower use of hormone 
replacement therapy (Karim-Kos et al., 2008). Despite of the advances in research and 
treatment, breast cancer remains one of the most serious health problems.  
Numerous epidemiological factors are associated to the development of breast 
cancer. The female sex is considered to be a risk factor. Men can also suffer from this 
disease, but it represents only 1% of all breast cancers diagnosed. The risk of 
developing increases with increasing age. The most common occurrence in women is 
between the 50 and 60 years old being the majority of breast cancer diagnosed after the 
age of 60 [3]. Lifestyle factors related to energy balance, including dietary behaviour, 
weight and physical activity, can also contribute to cancer risk. Fuemmeler et al. (2009) 
carried out a study suggesting that unhealthy behaviours developed early in life and 
persisted over time may increase the risk of some cancer types, such as premenopausal 
breast cancer.   
Figure 1. 
Estimated incidence and mortality 
in women from Czech Republic 
(2006); age standardized rate 
(European) per 100,000 [2]  
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The environment is also considered to have an influence on cancer development. 
Hormonally active agents found in the environment, for example  organochlorine 
pesticides, like dichlorodiphenyltrichloroethane (DDT) and its metabolite dichloro-
diphenyldichloroethylene (DDE) are suspected to influence breast cell proliferation by 
acting as estrogen or by disrupting pathways leading to cell proliferation (Snedeker, 
2001). In addition, 5-10% of malignant breast tumours can arise from hereditary 
predispositions.  Mutation in the tumour-suppressor genes BRCA1 or BRCA2 are 
strong predictors of breast cancer onset. The individuals carrying mutations in one of 
these genes have a 40-80% chance of developing this disease (Fackenthal and Olopade, 
2007). Mutation prevalence varies among different geographic regions and ethnic 
groups. Other mutations in genes, which encode proteins controlling cell cycle, cell 
growth and proliferation as well as signalling pathways, contribute to increased risk of 
cancer development.  
It is well established that higher risk of developing cancer is associated with 
high-dose radiation treatment, increased density of  breast tissue or hyperplasia, early 
menarche (before 12 years) and late menopause (after 50 years), having first child after 
30 years, use of oral contraceptives or long-term hormone replacement therapy (more 
than 5 years) to relieve menopausal problems, excessive drinking of alcohol, obesity 
and overall unhealthy life style (Russo et al., 2003). There are also some differences 
between races and ethnicities. White women are more susceptible than African 
American, but African American women are more likely than white women to be 
diagnosed with large tumours and distant-stage disease. Other ethnic groups have lower 
incidence rates (Ghafoor et al., 2003). 
 
1.2 Estrogens 
Estrogens are a group of steroid hormones which can easily pass through cell 
membrane and induce gene expression. They are the primary female sex hormones 
produced mainly by the adrenal cortex and ovary but also by the corpus luteum and 
placenta in response to impulses from the hypothalamic-pituitary axis. Some small 
percentage of estrogen is produced by other tissues such as liver, adrenal gland, 
mammary gland and adipose tissue.  
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In fact estrogens include three hormones: estradiol, estriol and estrone. The most 
potent is estradiol, which also have highest affinity for its receptors and is produced in 
the large quantities by the ovaries. Estrone is less potent metabolite of estradiol 
produced from androstenedione in adipose tissue during menopause. Estriol, the third 
endogenous estrogen originated also from estradiol, is produced by placenta during 
pregnancy. In non-pregnant women is found in smaller quantities (Chen et al., 2008).  
Estrogens influence many physiological processes like regulation of female 
reproductive organs, proliferation of endometrium and other aspects of the menstrual 
cycle, promoting formation and maintenance of female secondary sex characteristics. 
They also play a significant role in the metabolism. By reducing bone resorption 
estrogens prevent the development of osteoporosis (Hodek et al., 2005). It is well 
known, that post-menopausal women, whose ovaries ceased estrogen production may 
start suffering from osteoporosis. In liver cells, estrogens alter the production of 
proteins that influence cholesterol levels in the blood. There are two types of 
lipoproteins produced by the liver cells. Low density lipoprotein (LDL) can promote 
plaques formation on the arteries’ wall, whereas high density lipoprotein (HDL) inhibits 
plaques formation and carries cholesterol back to the liver. Thus estrogen’s action on 
liver cells decreases levels of LDL and increases HDL levels that help to reduce the risk 
of coronary diseases. They also have an influence on brain functions. For example 
estrogens have started to be used for treatment of Alzheimer disease in women, as they 
may affect brain function by avoiding effects of apolipoprotein E and beta-amyloid 
(Rokyta, 2000).  
Although estrogens have many beneficial effects they can also be harmful. By 
promoting cell proliferation they may contribute to accumulation of spontaneous 
mutations. Later, especially mutations in tumour suppressor genes or proto-oncogenes 
can lead to uncontrolled proliferation and the onset of cancer [4].  
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1.3 Estrogen receptors 
Estrogen action on target tissues is mediated through two estrogen receptor 
subtypes, ER-α and ER-β  that belong to the nuclear receptor superfamily of proteins 
(Ascenzi et al., 2006; Meyer et al., 2009; Vasudevan and Pfaff, 2008; Zilli et al., 2009). 
ERs have specific expression, but with overlapping distribution in some tissues. ER-α is 
expressed predominantly in the uterus, pituitary gland, ovaries, liver, kidneys, adrenals, 
and the mammary glands, while ER-β is expressed more in prostate, bones, ovaries, 
lungs, and in various parts of the central and peripheral nervous system (Matthews and 
Gustafsson, 2003; Zilli et al., 2009).  
ER-α and ER-β are encoded by distinct genes located on chromosome 6 and 14, 
respectively. There are several splicing variants of both receptors but their biological 
function remains unclear. Estrogen receptors like other steroid receptors share a well-
defined domain structure (figure 2).  
 
 
The A/B domain localized at the N-terminus contains the ligand-independent 
transcriptional activation function 1 (AF1), which allows the receptor to stimulate the 
transcription. The C domain refers to the DNA-binding domain (DBD) and is also 
responsible for receptor dimerization. The D domain corresponds to the hinge region. 
The E domain is involved in the ligand-binding and receptor dimerization and harbours 
 
Fig. 2.  Schematic representation of human estrogen receptor α and β. Numbers outside each box  
correspond with amino-acid number. There is also shown a percentage of amino-acid homology 
(Zilli et al., 2009).  
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the ligand-dependent transcriptional activation function 2 (AF2) and the F domain is 
localized at the C-terminus. Because of the high degree of sequence identity within 
DNA-binding domain (97%), ER-α and ER-β bind the estrogen responsive element with 
similar affinity and specifity. The ligand binding domain has a certain degree of amino 
acid homology and both receptors exhibit similar affinity to endogenous estrogen. On 
the other hand, there is less than 20% amino-acid identity between A/B domain and C 
terminal F domain. These differences may contribute to different ER action on the 
target genes (Zilli et al., 2009). A comparison between AF1 domain of both receptors 
showed that, under the same conditions, the activity of AF1 of ER-β is minimal while 
this domain is very active in ER-α on a variety of estrogen responsive elements. These 
differences between the N-terminal regions could be a possible explanation for the 
distinct gene regulation and biologic responses (Matthews and Gustafsson, 2003).  
Both receptors are expressed in normal breast tissue, but only ER-α is necessary 
for growth of mammary ducts and normal ductal branching. The experiment with ER-α 
and ER-β knockout mice demonstrated that ER-α is closely associated with cancer 
development while ER-β exerts anti-proliferative and pro-differentiative functions.  
Thus, the loss of ER-β expression is considered to be involved in tumour progression 
(Matthews and Gustafsson, 2003; Zilli et al., 2009). Despite being discovered nearly ten 
years after ER-α, ER-β seems to act as major regulator of ER-dependent signalling 
pathway. In many cases, when ERs are coexpressed, ER-β exhibits an inhibitory action 
on ER-α mediated gene expression (Matthews and Gustafsson, 2003; Soldati et al., 
2009).  
1.4 Estrogen signalling pathways 
Both receptors act as ligand-activated transcription factors (Moggs and 
Orphanides, 2001). There are two main signalling pathways (figure 3): the genomic and 
non-genomic. In the classical genomic pathway in the absence of ligand ER is inactive 
and bound to heat-shock proteins (Hsp90 and Hsp70). Upon ligand binding ER 
undergoes structural changes, dissociation from the chaperon proteins and homo-, or 
heterodimerization and translocation to the nucleus (Ascenzi et al., 2006; Marino et al., 
2006; Zilli et al., 2009). In the nucleus dimers bind to a specific DNA sequence, defined 
as estrogen responsive element (Duffy et al., 2007), in the promoter region of estrogen-
15 
 
regulated genes which leads to the release of co-repressors and to the recruitment of 
specific co-activator proteins. These proteins induce up-regulation of genes involved in 
cell proliferation and survival and down-regulation of genes responsible for anti-
proliferative or pro-apoptotic activity (Vasudevan and Pfaff, 2008; Zilli et al., 2009). 
The above described classical pathway is dependent on the presence of ERE in the 
promoter of target genes, such as complement 3 and pS-2. The final response to the 
activation through genomic pathway occurs in hours.  
 
 
Fig. 3. Genomic and non-genomic estrogen signaling pathways (Zilli et al., 2009). 
Estrogens affect also the transcription of genes that do not have ERE sequence. 
They are regulated by other transcription factors binding to alternative regulatory DNA 
sequences. ER interacts with transcription factors like activating protein-1 (AP-1), 
cAMP-responsive element binding protein, NF-κB,  Jun/Foz, c-Jun/ATF-2 and Sp-1, 
stabilize their direct binding to DNA enhancing transcription of genes such as cyklin D1 
and insulin-like growth factor receptor-1 (IGFR1). The mechanism is referred as non-
classical genomic pathway  (Pietras and Marquez-Garban, 2007; Zilli et al., 2009). 
ER-α and ER-β show similar patterns of genes activation at classical ERE-containing 
target genes, although ER-β requires higher ligand concentration than ER-α, they 
exhibit completely different effects at non-classical AP-1 sites after estrogen binding. 
While ER-α activates, ER-β inhibits transcription. For example expression of cyklin D1 
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regulated by estrogens via AP-1 sites is stimulated by ER-α but inhibited by ER-β (Zilli 
et al., 2009).   
Some of the ERs are localized in the cell membrane and provide action that is 
initially independent on gene transcription and thus is referred as non-genomic pathway. 
Occurring via protein-protein interaction with other transcription factors and signalling 
complexes that, in turn, mediate gene expression (Pietras and Marquez-Garban, 2007). 
Non-genomic action of estrogen results in rapid cellular response (milliseconds to 
minutes) associated with increased calcium levels and activation of intracellular kinase 
cascades, including phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein 
kinase (MAPK), protein kinase A and protein kinase C (Chen et al., 2008; Marino et al., 
2006; Matthews and Gustafsson, 2003; Vasudevan and Pfaff, 2008). Membrane-
associated ER undergoes post-translation modification such as palmitoylation of Cys 
447 in the ligand-binding domain of ER-α and is targeted to calveolin-1 localized in 
lipid rafts. Lipid rafts are cholesterol and sphingolipids-rich domains in cell membrane 
that provide a matrix for signal transduction. Upon estrogen binding membrane ERs 
form dimers and interact with adaptor proteins resulting in activation of  membrane 
growth factor receptors as epidermal growth factor receptor (EGFR), human epidermal 
growth factor receptor 2 (HER2) and insulin-like growth receptor factor (IGFR1). In 
conclusion, non-genomic activity is influenced by the overall signal transduction 
pathways and is highly dependent on co-regulatory proteins. ERs and its co-regulators 
represent targets for phosphorylation by cytoplasmatic kinases leading to activation of 
nuclear ER-driven transcription (Chen et al., 2008; Katzenellenbogen, 1996; Pietras and 
Marquez-Garban, 2007; Zilli et al., 2009). Both nuclear and extranuclear estrogen 
receptors can interact cooperatively with transmembrane growth factor receptor 
signalling pathways and this cross communication between ERs and GFRs promoters 
downstream signalling for tumour cell survival, proliferation and also endocrine 
resistance. Understanding this signalling pathways is necessary for development of new 
therapies, that will affect this signal transduction (Pietras and Marquez-Garban, 2007). 
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The first and also rate-limiting reaction in the formation of steroid hormones is 
the conversion of cholesterol to pregnenolone. Pregnenolone is sometimes referred to as 
„mother“ steroid because once created it is converted to androgens or estrogens via 
subsequent reactions catalyzed by steroid dehydrogenases and hydroxylases [5]. The 
last step of estrogen biosynthesis is catalyzed by aromatase, a member of the 
cytochrome P450 superfamily, that converts androstenedione and testosterone to estrone 
(E1) and estradiol (E2), respectively (Simpson et al., 2002).  
In premenopausal women the main amount of estrogen production comes from 
ovarian steroidogenesis while in postmenopausal women, whose ovaries decline 
estrogen formation, the main source of estrogens is extragonadal sites. Estradiol 
concentrations in breast tissue in premenopausal and postmenopausal women are 
similar in spite of the decrease of plasma levels in menopause (Castagnetta et al., 1996). 
Moreover levels of estrogens in women with and without tumours do not differ 
(Thijssen, 2004). It was also determined, that E2 concentration present in breast tumour 
tissues in postmenopausal woman, is 20-fold higher than in the plasma (Simpson and 
Davis, 2001). The absence of correlation between estrogen levels in circulation and in 
tissue suggests that there are local factors responsible for the accumulation of relatively 
high concentrations of estrogens in breast tissue (Castagnetta et al., 1996; Thijssen, 
2004). Within peripheral tissues estrogens are not synthesized de novo, because 
extragonadal sites are not able to convert cholesterol to the C19  steroids, but are 
generated locally from circulating C19 precursors as androstenedione, 
dehydroepiandrosterone (DHEA) and DHEA sulfate rising in the adrenal cortex. For 
this reason circulating levels of androgens play an important role,  providing the 
substrate for estrogen biosynthesis in these sites (Simpson et al., 2002; Simpson and 
Davis, 2001). There are two important steroidogenic reactions occurring in peripheral 
tissues. The first is the conversion of androgens to estrogens in adipose tissue that has 
high activity of aromatase and after menopause becomes the main source of estrogen. 
The second is transformation of testosterone to dihydrotestosterone (DHT) in the skin 
[5]. It seems that androgens might be more important for maintaining local level of E2 
than circulating estrogens.  
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1.7 Aromatase  
Estrogen biosynthesis is catalyzed by aromatase, a microsomal enzyme, that 
belongs to the cytochrome P450 superfamily and is encoded by the CYP19 gene. The 
cytochrome P450 multicomponent mono-oxygenase system cooperates with its redox 
partner NADPH-cytochrome P450 reductase (CPR) that contains flavins, FAD and 
FMN, and catalyze transfer of electrons from NADPH to aromatase. Estrogen synthesis 
is a three-step process (figure 6). Each step requires 1 mol of O2 and 1 mol of NADPH. 
Upon receiving electrons from CPR aromatase converts androgens (C19) to estrogens 
(C18) by three successive hydroxylations (Hong et al., 2009). The first and second 
hydroxylations occur at the 19-methyl group of androgen and the third step involves 
cleavage of the bond between C10 and C19 and the aromatization of the steroid A-ring. 
The aromatization step is still poorly understood although it has been studied for more 
than 35 years (Ghosh et al., 2009). 
 
 
Fig.6:     Mechanism of last step in estrogen biosynthesis catalyzed by aromatase [6].  
 
Aromatase expression is under the control of tissue specific promoters regulating 
alternative splicing mechanism in various sites. In ovaries expression is primarily 
mediated by promoter II, in placenta by promoter I.1 and in adipose tissue and skin by 
promoter I.4. Tumours produce factors, that stimulate local aromatase expression, that is 
associated with aromatase promoter switching from glucocorticoid-stimulated promoter 
I.4 in normal tissue to cAMP-stimulated promoters I.3 and II in cancerous tissues 
(Chen, 1998; Simpson et al., 2002).  
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Since estrogens play an important role in breast cancer development there has 
been a long-term interest in the structure-function relationship and many attempts to 
elucidate aromatase structure have been done. In a recent work, Ghosh et al. (2009) 
revealed the crystal structure of human aromatase (figure 7). These findings clarified the 
molecular mechanism of androgens conversion to estrogens and are very important for 
the development of new aromatase inhibitors for prevention or/and treatment of 
hormone-dependent breast cancer (Hong et al., 2009).   
 
 
 
 
 
 
 
Fig. 7: The structure of human aromatase 
P450 enzyme (Ghosh et al., 2009).  
 
1.8 Breast cancer therapies 
Breast cancer can be prevented by surgical (bilateral mastectomy or 
oophorectomy) or by endocrine approaches (tamoxifen or raloxifene). There is a high 
percentage of estrogen receptor positive breast cancer and for this reason there are lot of 
efforts to develop drugs, that block the estrogen receptors (anti-estrogens like 
tamoxifen) or prevent the synthesis of estrogens (aromatase inhibitors). 
Tamoxifen, the pioneering synthetic selective estrogen modulator (SERM), was 
the first drug developed for treatment of estrogen receptor positive breast cancer. It also 
became the first drug, that was approved by the United States Food and Drug 
Administration for the prevention in high risk women (Oseni et al., 2008). Tamoxifen is 
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a synthetic non-steroidal agent that binds to the both ERs with equivalent affinity and 
induces conformation changes. These changes result in different amino acids exposure 
on the receptor and also promote the binding of co-regulators, which  determine the 
biologic activity of the SERM at the affected tissues (Johnston and Dowsett, 2003). In 
conclusion, SERMs show partial agonist and also antagonist activities depending on the 
tissue type. For example tamoxifen is an antagonist in breast tissue, but it acts as partial 
agonist on the endometrium (Dutta and Pant, 2008). Except increased risk of 
endometrial cancer there are other side effects including formation of blood clots and 
stroke, decrease of bone density in pre-menopausal women and fertility issues along 
with hair and nail thinning (Johnston and Dowsett, 2003). Despite of these side effects 
tamoxifen has been the gold standard for treatment of ER-positive breast cancer for 
many years and has saved thousands of women´s lives. Another SERM, Raloxifen, 
which was primarily used for osteoporosis treatment, has also shown significant 
reduction in breast cancer development even with better side effect profile than 
tamoxifen. Besides SERMs, there is a group of selective estrogen receptor degradation 
agents (SERDs) such as fulvestrant. They directly target estrogen receptor and cause its 
degradation.  
Other alternative approach is treatment with aromatase inhibitors (AIs). 
However, this approach is suitable only for post-menopausal women. AIs are 
categorized into two types, steroidal and non-steroidal depending on their structure and 
mechanism of action. Steroidal aromatase inhibitors are analogues to androgens 
structure and compete with aromatase substrate for binding to the active site. Non-
steroidal inhibitors interact  directly with heme prosthetic group of aromatase (Dutta 
and Pant, 2008; Chen, 1998). The first aromatase inhibitor was aminoglutethimide, but 
lack of specifity and presence of side effects including liver toxicity, cortisol production 
inhibition and hypothyroidism led to the withdrawal of its use (Dutta and Pant, 2008) 
and development of second generation aromatase inhibitors like Formestane 
(4-hydroxyandrostenedione; 4-OHA) and Fadrozole (non-steroidal counterpart of 
4-OHA). Formestane, a steroidal inhibitor, showed high efficacy against ER-positive 
breast tumours, but it was ineffective in patients with no prior endocrine therapy 
response. Moreover, formestane has to be administrated by muscular injections. Second 
generation did not receive a lot of attention, because third generation quickly followed. 
Third generation include the non-steroidal inhibitors anastrazole and letrozole, and the 
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steroidal exemestane. This class of therapeutics were developed to fight against breast 
cancer cases that do not respond to tamoxifen treatment. They have minimal harmful 
effects and are highly selective in comparison with previous aromatase inhibitors (Dutta 
and Pant, 2008).  
Despite of significant success in improving the survival rates among breast 
cancer patients there is a risk of developing resistance to the available therapeutic 
approaches. Further investigations of new compounds with aromatase inhibitors 
features are required for ongoing combat of ER-positive breast cancer.  
 
1.9 Flavonoids 
Flavonoids, derived particularly from soya, have started to be examined because 
of a low incidence of breast cancer that has been noticed in countries with high soy 
intake. This observation has led to the extensive research of a potential role for 
phytestrogens in preventing breast cancer development (Oseni et al., 2008). Initial 
excitement over the putative anticancer features of soya was proved in 1966 by Folman 
and Pope (1966), who were the first to demonstrate anti-estrogenic effects of 
isoflavones. Later it was discovered that isoflavone genistein can act as a specific 
inhibitor of tyrosine protein kinase (PTK), which is frequently over-expressed in cancer 
cells. Nowadays genistein is thought to be able to inhibit the activity of many enzymes 
including topoisomerase II, PTK (Peterson and Barnes, 1996), 17β-hydroxysteroid 
dehydrogenase (Brooks and Thompson, 2005) and  aromatase (Messina and Loprinzi, 
2001). 
Flavonoids can be categorized into flavones, flavanols, isoflavones, flavonols, 
flavanones, and flavanonols according to the saturation level and opening of the central 
pyran ring. The most common form of flavonoids is isoflavones that are found in 
a variety of plants, but the highest dietary source is soya. There are two main 
isoflavones, genistein and daidzein, present in soy, in their β-D-glycosides form the 
genistin and dadzin. The intestinal bacteria contain glucosidases that hydrolyze 
glycosidic bonds and produce aglycone forms of isoflavones that are biologically active 
(Oseni et al., 2008).  
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Soya foods, because of a number of health benefits, have become very popular 
among non-Asians. In Japan and China adult people consume between 25-50 mg 
isoflavones per day. In contrast, daily soya intake is quite low in the Western countries-
typically less than 3 mg/day, however among vegetarians and health-conscious 
individuals amounts of soya foods are much higher (Messina and Wood, 2008). The 
modest consumption of isoflavones (less than 100 mg/day) showed favourable effects in 
humans, such as enhancing arterial compliance and reducing urinary levels of 
5-hydroxymethyl-2-deoxyuridine, which is a marker of oxidative DNA damage 
(Messina and Loprinzi, 2001). 
Flavonoids are a group of substances that have structural similarity to estradiol. 
The presence of the phenolic ring allows them to bind to estrogen receptors and induce 
a similar response. Due to this feature they are called phytestrogens. It has been 
discovered that they have estrogen agonistic and antagonistic effects (Oseni et al., 2008) 
and for this reason, they are sometimes classified as selective estrogen receptor 
modulators (SERMs) (Messina et al., 2006). In comparison with SERMs that in general 
can bind to ER-α or ER-β with similar affinity, phytestrogens appear to bind to ER-β 
with greater preference. This action may explain how phytestrogens can be protective 
against breast cancer, because binding to ER-β leads to mammary cell growth inhibition 
as well as inhibition of ER-α stimulatory effect. Phytestrogens are considered to be 
weakly estrogenic, having 10-5-10-2  less activity per mole compared with 17β-estradiol. 
However, in some in vitro studies isoflavones exhibited estrogenic effects even greater 
than estradiol (Duffy et al., 2007). In vitro examinations of estrogenic and anti-
estrogenic potential of isoflavones have shown that genistein acts primarily as an 
agonist of ER-β and that the different transcriptional actions of estrogens and 
isoflavones result not only from distinct binding affinities but also from different ability 
to  recruit co-regulators and trigger transcription function of ERs. 
As mentioned above, isoflavones have been shown to inhibit several important 
enzymes involved in estrogen metabolism. Namely aromatase, a cytochrome P450 
enzyme, responsible for the production of estrogens from androgens, 17β-
hydroxysteroid dehydrogenase convert estrone (E1) to a more potent compound, 
estradiol (E2). Low micromolar concentrations of isoflavones inhibit 3β-hydroxysteroid 
dehydrogenase converting dehydroepiandrosterone into androstenedione, that can be 
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subsequently converted to estrone (Messina and Loprinzi, 2001). Isoflavones also 
inhibit several types of cancer cells in vitro including ER-dependent as well as ER-
independent cancer cell lines. Further, isoflavones exert anti-inflamatory, anti-
atherogenic, anti-allergic and antioxidant activity and inhibit angiogenesis. Isoflavones 
are  also considered as an alternative to hormone therapy in post-menopausal women 
(Helferich et al., 2008).  
A variety of health benefits have been attributed to soya consumption, but there 
is also a concern arisen over their estrogenic properties, that may increase the risk of 
recurrence or stimulate growth of pre-existing tumours. There are some studies 
showing, that genistein in vitro stimulates the growth of ER-positive mammary cancer 
cells. In vivo, ovariectomized athymic mice dietary feeded with genistein exerted the 
stimulation of growth of existing ER-positive breast tumours (Messina et al., 2006). The 
role of phytestrogens in breast cancer prevention remains unclear. The impact of soya 
intake on breast cancer patients and woman at high risk of this disease needs to be better 
understood. 
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2. AIM OF THE STUDY 
There are several terapeutic approaches for treatment of ER-positive breast 
cancer. The inhibition of the aromatase enzyme is one of them. Aromatase is 
responsible for catalyzing the last step of estrogen biosynthesis – a conversion of 
androstenedione and testosterone to estrone and estradiol, respectively. On the other 
hand, there is a strong evidence that isoflavones have the ability to bind estrogen 
receptors and  are important inhibitors of carcinogenesis. Moreover, some studies have 
shown that these compouns inhibit cell proliferation of different cancer cell lines. 
However, the mechanism by which ginestein and dadzein modulates growth of breast 
cells and prevents breast  cancer are not fully understood. In that way, the aim of this 
study was to investigate if the soya extract biotransformed by fungi Aspergillus 
awamori, which contains ginestein and daidzein, was able to inhibit aromatase activity, 
in placental microsomes and in MCF-7aro cells, an estrogen dependent human breast 
cancer cell line stably transfected with the aromatase gene. This cell line will also be 
used to evaluate  the potential effects of the biotransformed soya extract on breast 
cancer cell proliferation.  
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3. MATERIALS AND METHODS 
3.1 Materials 
The soya extract biotransformed by fungi Aspergillus awamori was obtained 
from the laboratory of Prof. Maria José Vieira Fonseca and Prof. Maria Regine Torqueti 
of Faculty of Pharmacy of Ribeirão Preto, University of São Paulo in Brazil. Eagle´s 
essential minimum medium (MEM), phenol red free medium, fetal bovine serum, 
antibiotics penicilin-streptomycin-amphotericin B, Geneticin (G418), trypsin and L-
glutamin were purchased from Gibco Invitrogen Co. (Parsley, Scotland, UK). 
Formestan (4-OHA), testosterone, reduced form of nicotinamide adenine dinucleotide 
phosphate (NADPH), ethylenediamine tetraacetic acid (EDTA), trypan blue, 
dimethylsulphoxide (DMSO), dextran, charcoal and sodium pyruvate were obtained 
from Sigma-Aldrich Co. (Saint Louis, USA). Tritiated androstenedione was purchased 
from Perkin-Elmer (Boston, USA). Scintillating liquid cocktail was from ICN 
Radiochemicals (Irvine, USA), dye reagent for Bio-Rad protein assay was supplied by 
Bio-Rad (München, Germany). Tritiated thymidine was from Amersham (Amersham 
International, Amersham, UK). MCF-7aro, the ER-positive human breast cancer cells 
stable transfected with human placental aromatase gene and selected with geneticin 
were kindly supplied by Prof. Shiuan Chen from the Beckman Research Institute (City 
of Hope, Duarte, CA, USA). 
 
3.2 Methods 
3.2.1 Preparation of charcoal pellets 
To prepare charcoal pellets a suspension of 5% charcoal, 0,5% dextran in PBS 
was prepared and 1 ml of this mixture was put into each microcentrifuge tubes and 
centrifuged at 14 000 g for 10 min. The supernatant was removed and the charcoal 
pellets were dried. For in-cell aromatase assay the volume was reduced to 500 μl of 
charcoal-dextran mixture. 
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3.2.2 Preparation of charcoal dextran heat-inactivated FBS  
The fetal bovine serum was inactivated at 56 ºC for 1 h. Then, 500 ml of heat-
inactivated FBS was treated with 8 g activated charcoal at room temperature during 
24 h, 5-6 times centrifuged at 4000 g/15 min and passed through 0,22 μm filter to 
separate the charcoal from the serum. 
3.2.3 Preparation of placental microsomes 
Aromatase inhibition studies were performed using human placental microsomes 
that contain a high level of aromatase. Placental microsomes were obtained as described 
by Yoshida and Osawa (1991), with some modifications. Human placentas delivered 
from a local hospital were placed in cold 67 mM potassium phosphate buffer (pH 7,4) 
that contained 1% KCl. All procedures were performed at 0-5 ºC. The cotyledon tissue 
was separated and homogenized in a Polytron homogenizer with 67 mM KH2PO4 (pH 
7,4) containing 0,5 mM dithiotreitol (DTT,1:1,w/v) and 0,25 M sucrose. The 
homogenate underwent a differential centrifugation. First it was centrifuged at 5000 g 
for 30 min. Then the supernatant was taken and centrifuged twice at 20 000 g for 30 
min and at 54 000 g for 45 min to obtain the microsomal pellet. The microsomes were 
washed and resuspended in 67 mM potassium phosphate buffer (pH 7,4), which 
contained 0,25 M sucrose, 20% glycerol and 0,5 mM DTT and stored at -80 ºC. The 
protein concentration was determined by Bradford protein assay using bovine serum 
albumin as a standard. 
3.2.4 Aromatase assay procedure 
Aromatase activity was measured according to Thompson and Siiteri (1974). 
This procedure is based on the evaluation of the amount of tritiated water released from 
radiolabeled androstenedione, during the aromatization reaction. The soja extract was 
dissolved in DMSO and diluted in 67 mM potassium phosphate buffer (pH 7,4). The 
reaction mixture, of total volume 1 ml, contained 20 μg of protein of the microsomes, 
different dilutions of the soya extract (corresponding to the concentration 1,97 μM, 
3,9 μM and 5,9 μM of Daidzein and the concentration 1,48 μM, 2,9 μM and 4,44 μM of 
Genistein), 40 nM of [1β-3H] androstenedione and an appropriate amount of  KH2PO4 
to complete the final volume of 1 ml. As a positive control 0,5 μM formestane was 
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used. The blank contained the same substances except the extract. The reaction was 
initiated by the addition of 150 μM reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) and incubated in a shaking water bath at 37 ºC, for 15 minutes. To 
stop the reaction 250 µl of 20% TCA was added into each tube. Then the mixture was 
transferred to the eppendorf  tubes with pre-made charcoal-dextran pellet, vortexed and 
incubated at room temperature, for 1 hour. After the centrifugation at 14000 g, for 10 
minutes the supernatants were transferred into new charcoal-dextran pellets, vortexed, 
incubated for other 10 minutes and centrifuged  under the same conditions. The 
supernatant from each tube was transferred to empty eppendorf tubes and centrifuged to 
avoid the presence of the charcoal, which could cause some interference. Then, 600 µl 
aliquot of supernatant containing the tritiated-water product was mixed with 3 ml of a 
liquid scintillating cocktail and measured in a liquid scintillation counter. Experiments 
were performed in triplicate.  
3.2.5 Cell cultures 
MCF-7aro is a human breast ER-positive cancer cell line which was stably 
transfected with aromatase gene. To maintain the cell line in culture, cells were seeded 
in 75 cm2 plastic flasks with a standard MEM medium containing Earle´s salt, 2 mM L-
glutamine, 1mM sodium-pyruvate, 1% penicillin-streptomycin-amphotericin B, 70 
ng/ml geneticin (G418) and 10% heat-inactivated FBS and incubated  at 37 ºC with 5% 
CO2 atmosphere. The medium was changed every 3 days. When the cells reached 80-
90% of confluence, they were washed with PBS and incubated with 2 ml of 0,25 % 
trypsin with 1mM EDTA,  for 2 min, at 37 ºC. The flask was rinsed with medium 
containing FBS to stop the action of trypsin. The detached cells were taken out and 
centrifuged at 400 g, at 4 ºC, for 6 min. The pellet was resuspended in MEM and seeded 
into new flasks. In order to count the cells after trypsinization an aliquot was mixed 
with the vital dye Trypan Blue 0,1% (1:1) and the viable cells (a viable cell does not 
stain with trypan blue) were counted under the microscope using a Neubauer chamber.  
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3.2.6 In-cell aromatase activity 
Aromatase converts androgens to estrogens through three hydroxylations and 
during this reaction product is released from androst-4-ene-3,17-dione. Aromatase 
activity was determined according to Thompson and Siiteri (1974) with modifications.  
MCF-7aro cells (1x106 cells/well) were cultured in 24-well plates in 500 µl 
Eagles’s minimum essential medium (MEM) with 10% heat-inactivated fetal bovine 
serum (FBS). When the cells were confluent, they were washed with PBS and cultured 
in 300 µl serum-free medium (MEM) with 50 nM [1β-3H] androstenendione and 500 
nM progesterone (to supress 5α-reductase, which also metabolizes androstenedione), 
and soya extract containing 5,7 μM to 57 μM of Genistein and 7,6 μM to 76,0 μM of 
Daidzein. The cells were incubated for 1 hour at room temperature. The reaction was 
stopped by addition of 100 µl TCA 20%. The content of each well was transferred to 
pre-made charcoal-dextran pellets, incubated for 1 hour at room temperature and 
centrifuged at 14 000 g for 10 minutes. Then, the supernatant was taken to other 
charcoal-dextran pellets and incubated for 10 minutes. After centrifugation 200 µl of the 
supernatant were mixed with 3 ml of liquid scintillation cocktail and the percentage of 
inhibition was determined in scintillation counter (LS-6500, Beckman Coulter). All 
tests were carried out in triplicate. As a positive control formestane at 1 μM was used. 
The blank contained cells in serum-free medium without soya extract. In order to 
determine the protein content, that corresponds to the obtained aromatase inhibition, 
cells were lysed with 1 ml of 0,5 M NaOH, overnight at room temperature under 
constant agitation, and protein concentration was evaluated by the Bio-Rad Protein 
Assay. 
3.2.7 Bio-Rad Protein Assay 
The procedure is based on the method of Bradford with the binding of 
Coomassie Blue G-250 to proteins. The unknown concentration of protein was 
determined by comparison to a standard curve using bovine serum albumin (BSA) as a 
standard. The BSA was diluted with distilled water to obtain the concentration of 0,1 
mg/ml and 10, 20, 30, 40 and 50 µl of this solution were pipeted into a 96-well plate 
and H2O was added to total a volume of 160 µl. The sample of unknown concentration 
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was also diluted with H2O. The Bradford Reagent (40 µl) was added and the absorbance 
was measured at 595 nm. All determinations were done in triplicate.  
3.2.8 Thymidine incorporation assay 
To evaluate DNA synthesis the thymidine incorporation assay was used. In order 
to prevent estrogenic effects of FBS and phenol red (Wesierska-Gadek et al., 2007) the 
cells were cultured three days before the assay in  phenol-red free medium containing 
1mM sodium-pyruvate, 2mM L-glutamine, 1% penicillin-streptomycin-amphotericin B 
and 5% charcoal-stripped heat-inactivated fetal bovine serum (CFBS). Cells were 
seeded in 96-well plate in a density of 2,5 x 104 cells/ ml, in 200 µl of the above-
mentioned medium with 1 nM testosterone and different concentrations of soya extract 
(corresponding to 1,5 μM, 750 nM, 325 nM and 50 nM of Genistein and 1,92 μM, 958,5 
nM, 415 nM and 64 nM of Daidzein) and incubated for 48 hours at 37°C. The 
[3H]-thymidine was added to each well 8 hours before the assay. To lyse the cells 
a cycle of freezing/unfreezing was carried out. Then, every liquid were sucked out using 
the semi-automated cell harvester (Scatron Instruments, Norway) and the DNA was 
retained in a special filter. The filter circles were put into the tubes  with 1 ml of 
scintillation liquid to determine the [3H]-thymidine incorporation in DNA, using 
scintillation counter (LS 6500, Beckman Coulter). The blank did not contain soya 
extract only the appropriate medium. All the experiments were done in triplicate.  
3.2.9 Giemsa staining 
For the cell morphology study the Giemsa staining was used. Cells were seeded 
in 8 well chamber slides in a density 6 x 104 cells/ ml in 400 μl of phenol-red free 
medium with 1 nM testosterone and incubated with soya extract for 48 hours at 37°C 
under the same conditions as referred for the thymidine incorporation assay. Then, the 
incubation medium was removed, cells were washed with PBS, fixed with methanol 
(400 μl into each well) for 30 minutes, at room temperature. After washing with PBS 
the cells were incubated with Giemsa stain for 30 minutes at room temperature, then, 
washed with tap water and mounted in DPX (a mixture of Distyrene, a plasticizer, and 
xylene).  
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3.2.10 Preparation of the soya extract samples 
The biotransformed soya extract, prepared by Prof. Maria Regine Torqueti from 
the Faculty of Pharmacy of Ribeirão Preto, University of São Paulo, Brazil, contained 
a mixture of two isoflavones, genistein and daidzein in different concentrations. The 
sample was obtained as an extract, which was dissolved differently depending on the 
procedure: 
- For aromatase assay in microsomes the extract was dissolved in DMSO (100 µl) 
and PBS (900 µl) to obtain the mother solution of 116 mg/ml that was 
subsequently diluted to 5 mg/ml solution containing 5 ug/µl of daidzein and 4 
μg/µl of genistein.  
- For in-cell aromatase assay the extract was dissolved in DMSO (500 µl) and 
serum-free medium (500 µl) to obtain the mother solution of 116 mg/ml that 
was subsequently diluted (1:2) to 58 mg/ml solution containing 58 ug/µl of 
daidzein and 46,4 μg/µl of genistein.  
- for thymidine incorporation assay the extract was dissolved in DMSO (500 µl) 
and phenol-red free medium with charcoal-stripped heat-inactivated fetal bovine 
serum (500 µl) to obtain the mother solution of 116 mg/ml that was 
subsequently diluted (1:2,9) to 40 mg/ml solution containing 40 μg/µl of 
daidzein and 32 μg/µl of genistein. 
 
All the stock solutions were stored in  -20 ºC. For further dilutions an 
appropriate medium or buffer was used. The non-biotransformed soya extract was 
obtained as a mixture of genistein and daidzein in a concentration of 5 μg/ml of 
daidzein and 4,81 μg/ml of genistein. The preparation of the extract was as for the 
biotransformed soya extract. 
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4. RESULTS 
4.1 Evaluation of the aromatase activity in microsomes 
The biotransformed soya extract was firstly screened for putative aromatase 
inhibition properties. For this reason, we evaluated the aromatase activity, in placental 
microsomes, in the presence of 300 µl, 200 µl and 100 µl of the extract with 5 mg/ml of 
total concentration of isoflavones. These volumes corresponded to the concentrations of 
genistein and daidzein shown in Table 1. For comparison, there are also shown the 
concentrations of the isoflavones in non-transformed samples. The results suggest that 
our extract is able to inhibit aromatase activity in a dose-dependent manner (figure 8). 
For 10,34 µM, 6,8 µM and 3,45 µM of total concentration of isoflavones in the 
biotransformed soya extract we obtained 87,3%, 69,8% and 40,4% of aromatase 
inhibition, respectively. 
Table 1. Concentration of isoflavones in the soya extracts (biotransformed and non-biotransformed)  
Volume of biotransformed soya extract Concentration of Genistein(G) and Daidzein (D) 
                         100 μl          1,48 μM of G + 1,97 μM of D (3,45 µM) 
                         200 μl          2,9   μM of G + 3,9   μM of D (6,8 µM) 
                         300 μl         4,44 μM of G + 5,9   μM of D (10,34 µM) 
Volume of non-biotransformed soya extract Concentration of Genistein (G) and Daidzein (D) 
                         100 μl          1,78 μM of G + 1,97 μM of D (3,75 µM) 
                         200 μl          3,56 μM of G + 3,9   μM of D (7,46 µM) 
                         300 μl         5,3   μM of G + 5,9   μM of D (11,2 µM) 
 
To find out if the biotransformation induced by the fungi had any influence in 
the anti-aromatase activity, we carried out an aromatase assay using a sample of soya 
extracts without fungi under the same conditions as for the biotransformed one. The 
results are only preliminary, though it was obtained 90,13%, 86,62% and  69,88% of 
aromatase inhibition, respectively  for 11,2 µM, 7,46 µM and 3,75 µM of total 
concentration of isoflavones in the soya extract (figure 9).  
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Figure 8.Dose-dependent inhibition of aromatase 
activity in microsomes. The results are presented as 
mean of three independent experiments each 
carried out in triplicate. 
Figure 9. Dose-dependent inhibition of aromatase 
activity in microsomes. This graph represents only 
preliminary results of aromatase inhibition in non-
biotransformed soya extract. 
 
Our results suggested that the non-transformed soya extract was more potent to 
inhibit aromatase activity (figure 9). This higher aromatase inhibition is probably due to 
a little difference in the total content of isoflavones in both extracts. The non-
transformed sample has a higher concentration of genistein. To compare concentration 
differences see Table 1. The total concentration of isoflavones that was able to induce 
50% of aromatase inhibition was of 4,5 μM (figure 10). 
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Figure 10. The effect of soya extract on aromatase activity. For aromatase activity and IC50 
determination were used 20 μg of placental microsomes, 40 nM of tritiated androstenedione 
and different concentrations of isoflavones presented as total sum of Genistein and 
Daidzein.   
 
4.2 Evaluation of anti-aromatase activity in MCF-7aro cell line 
 The placental microsomal assay showed that the isoflavones contained in the 
biotransformed soya extract were able to induce aromatase inhibition. Our further 
interest was to find out if the biotransformed soya extracts inhibited aromatase activity 
in MCF-7aro cells. This cell line is an ER-positive breast cancer cell line, stably 
transfected with the aromatase gene, which is consider being a good model to study 
compounds with anti-aromatase activity in breast cancer management.  
The in-cell aromatase assay was performed with 10μl, 20 μl, 40 μl, 80 μl and 
100 μl of soya extract that corresponded to 5,73 μM G + 7,6 μM D, 11,5 μM G + 15,2 
μM D, 22,9 μM G + 30,4 μM D, 45,9 μM G +60,8 μM D and 57,3 μM G + 76,0 μM D, 
respectively. The percentage of aromatase inhibition obtained was approximately 25% 
for the concentration of 13,35 μM and of 85% for the concentration of 53,3 μM,  while 
for the higher concentrations the inhibition was almost complete. Figure 11 shows the 
percentage of aromatase activity per μg of protein, presented as total content of both 
isoflavones. The concentration of total isoflavones in the extract that induced 50% of 
aromatase inhibition was 21 μM.  
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Figure 11.  Dose-dependent inhibition of aromatase activity in MCF-7aro cells. Concentration is shown 
as a total sum of genistein and daidzein contained in biotransformed soya extract. The results 
are presented as mean ± SD of three independent experiments each carried out in triplicate.  
 
 
 
 
4.3 Morphological studies 
To examine if biotransformed soya extract induced any morphological 
alterations in MCF-7aro cells, phase contrast microscopy and Giemsa staining were 
performed (figure 12). The untreated control cells did not show any morphological 
changes during 48 hours of incubation. After 48 hr of  treatment with the  lower 
concentration (50 nM of Genistein plus 64 nM of Daidzein), the cells did not show 
morphological alterations, though, a few non-adherent round cells and membrane 
blebbing, a characteristic for apoptotic cell death, was detected. For the highest 
concentration of isoflavones (1,5 μM of Genistein plus 1,92 μM of Daidzein) a massive 
cell death was observed. Almost all the cells were detached and there was abundant cell 
debris.  
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Phase contrast Giemsa staining 
Figure 12.  Morphological alterations of MCF-7aro cells treated for 48 hr with biotransformed soya extract in 
different concentrations. In pictures A-C are shown phase contrast microscopies while in pictures 
D-F are presented Giemsa staining. Untreated control cells in phase contrast (A) and stained with 
Giemsa (D) (magnification 400x) without any morphological changes. The images B and E 
(magnification 400x) represent cell treatment with low (0,11 μM) concentrations. Images C and F 
(magnification 100x) show a massive reduction in cell viability in response to the treatment with 
higher (3,42 μM)  concentrations of genistein and daidzein. 
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4.4 Evaluation of cell proliferation 
In order to investigate the direct effects of biotransformed soya extract on the 
proliferation of MCF-7aro cells, thymidine incorporation assay was performed. Cells were 
treated with different concentrations of isoflavones, corresponding to 3,42 μM (1,5 μM of 
genistein + 1,92 μM of daidzein), 1,71 μM (0,75 μM G + 0,9585 μM D), 0,74 μM (0,325 μM 
G + 0,415 μM D) and 0,11 μM (0,05 μM G + 0,064 μM D) as shown in figure 13. In the 
concentration of  0,11 μM  (0,050 μM of Genistein plus 0,064 μM of Daidzein) only a slight 
decrease in DNA synthesis was observed, while 0,74 μM (0,325 μM of Genistein plus 0,415 
μM of Daidzein) caused a reduction of 20% in cell proliferation. Above this latter 
concentration a dramatic decrease in DNA synthesis was detected.  
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Figure 13.  Effect of the soya extract on the rate of DNA synthesis. MCF-7aro cells cultured in steroid-
free medium without red phenol and treated with four different concentrations of 
biotransformed soya extract in medium containing 1 nM of testosterone. Cells treated only 
with testosterone represented maximum cell proliferation and were considered as a control. 
Results are shown as percentage of DNA synthesis and concentration of the soya extract as 
a total of genistein and daidzein.  
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5. DISCUSSION AND CONCLUSIONS 
Epidemiological studies have shown that high soya intake is associated with 
a reduced breast cancer risk. Though, it has also been shown that the isoflavones present 
in soya exhibit estrogen-like properties, inducing proliferation and estrogenic markers in 
MCF-7 cells. In order to clarify the mechanisms by which ginestein and dadzein, the 
predominant isoflavones present in soya, prevents breast cancer we examined the in 
vitro effects of soya extract on aromatase activity in human placental microsomes and in 
an ER-positive breast cancer cell line (MCF-7aro).  
We found that the biotransformed soya with the fungi Aspergillus awamori and 
non-transformed soya extract effectively inhibit aromatase activity in human placental 
microsomes in a dose-dependent manner. In addition, our results also showed that, in 
placental microsomes, the biotransformation of soya did not alter the capacity to induce 
aromatase inhibition. Preliminary results with the non-transformed sample showed 
greater aromatase inhibition. One possible explanation to this result may be the higher 
concentration of ginestein in this extract, which resulted in a slight increase in the total 
concentration of the isoflavones present in the extract. These findings are not so 
consistent with Le Bail et al. (2000), who found that isoflavonoids with the phenolic B 
ring in the 3 position on the pyran ring (genistein and daidzein), are not potent 
aromatase inhibitors, being a stronger 3β-hydroxysteroid dehydrogenase and/or 
17β-hydroxysteroid dehydrogenase inhibitors. In contrast, flavonoids with B ring at 
position 2 (7-hydroxyflavone, chrysin, apigenin) are more potent aromatase inhibitor. 
Moreover, Brooks and Thompson (2005) also reported, that genistein and daidzein has 
little or no ability to inhibit aromatase activity in placental microsomes, but modulate 
activity of 17β-hydroxysteroid dehydrogenase. Other authors studied various 
flavonoids, four flavones (for example chrysin), two isoflavones (genistein and biochain 
A), flavanone (naringenin) and napthoflavone and concluded that flavones are much 
more potent than isoflavones in inhibiting aromatase (Kao et al., 1998).  
Our results from aromatase assays in the cell line expressing high levels of 
aromatase also showed a dose dependent aromatase inhibition that is in agreement with 
what was observed in human placental microsomes. Higher concentrations were needed 
to obtain 50% of aromatase inhibition (21 μM) in the cell system in comparison to the 
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microsomal value. This might be explained by the simplicity of the placental 
microsomes system, where the enzyme is directly accessible to the inhibitors. In 
addition, as it has been described that isoflavonoids bind estrogenic receptors, these data 
may be also explained by the existence of other mechanisms, such as influence of 
estrogen receptors, growth factor receptors and others.  
As we showed that the soya extract has anti-aromatase activity and as it has been 
described that aromatase inhibitors have antiproliferative activity, it was also 
investigated its effects on cell morphology and on proliferation of MCF-7aro cells. 
Morphological studies demonstrated drastic morphological alterations depending on the 
concentrations used. The lowest concentration showed a slight reduction in cell density; 
the cultures presented well preserved cell morphology, a few non-adherent round cells 
and membrane blebbings, a characteristic of apoptotic cell death. The highest 
concentration of soya extract induced a massive cell death, with almost all the cells 
detached and abundant cell debris, showing that this concentration was toxic and 
probably induced necrosis.  
Preliminary results from the cell growth inhibition caused by genistein and 
daidzein showed that the proliferation of the MCF-7aro cells, induced by testosterone at 
concentrations within physiological range, was inhibited in a dose-dependent manner. 
In our study we found remarkable differences in cell proliferation between 
concentrations, while 0,74 μM of total concentration of isoflavones showed only 
a reduction of 20% of cell proliferation, the concentration of 1,71 μM induced 
a dramatic reduction in DNA synthesis. These results are in agreement with the 
observations in contrast phase microscopy and Giemsa staining. Nevertheless, these 
findings are not in accordance with other studies that demonstrated that isolated 
isoflavones present a biphasic effect on cell proliferation. In low concentrations (less 
than 10 μM) induce proliferation, whereas in higher (more than 10 μM) concentrations 
cause an antiproliferative effect (Brooks and Thompson, 2005). There is an evidence 
from in vitro and some in vivo studies that the anticancer activity of daidzein and 
genistein in breast cancer is mediated through cell cycle arrest and apoptosis (Jin et al., 
2010). Daidzein was found to arrest cell cycle at the G1 and G2/M phases in human 
breast cancer cells MCF-7 (Choi and Kim, 2008) and induced apoptosis via the 
mitochondrial pathway (Jin et al., 2010). Moreover, it has been demonstrated that 
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genistein also induces a G2/M cell cycle arrest in breast cancer and a dose-dependent 
decrease in the expression of cyclin B, which plays important roles in the positive 
regulation of CDK activity (Banerjee et al., 2008). In our study the highest 
concentration, of approximately 3,5 μM, showed 98% of reduction in cell proliferation 
suggesting that daidzein and genistein may have a synergestic effect, leading to a  more 
potent cell cycle arrest and/or cell death. Further studies have to be carried out within 
the range of concentrations used in order to understand the process of cell death. 
In summary, our preliminary data strongly suggest that the biotransformed soya 
extract acted as a potent aromatase inhibitor and has an antiproliferative activity in 
MCF-7aro cells. This work can open new research avenues for the elucidation of the 
mechanisms associated with the reduction of breast cancer cell growth, and may 
contribute to the potential use of these type of natural compounds for the treatment of 
breast cancer. However, further studies with increased number of experiments and 
proper statistical analysis are required for definitive conclusions.  
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6. ABBREVIATIONS 
AF1   transcriptional activation function 1 
AF2   transcriptional activation function 2 
AP-1 trancription factor controling cell differentiation, proliferation and   
apoptosis  
BRCA1  human tumor suppressor gene type 1 
BRCA2  human tumor suppressor gene type 2 
cAMP   cyclic andenosine monophosphate 
cDNA   copy deoxyribonucleic acid  
CFBS   charcoal-stripped heat-inactivated fetal bovine serum 
DBD   DNA-binding domain 
DMSO  dimethyl sulfoxide 
EDTA   ethylenediamine tetraacetic acid 
EGFR   epidermal growth factor receptor 
ERE   estrogen responsive element 
ERs   estrogen receptors 
ER-α   estrogen receptor α 
ER-β   estrogen receptor β 
FBS   fetal bovine serum 
GFRs   growth factor receptors 
HDL   high density lipoproteins 
HER2   human epidermal growth factor receptor 2 
IGFR1   insulin-like growth factor receptor 1 
LDB   ligand binding domain 
LDL   low density lipoproteins 
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MAPK  mitogen-activated protein kinase 
MEM   minimum essential medium 
NADPH  nicotinamide adenine dinucleotide phosphate (reduced form) 
NF-κB   nuclear factor kappa B 
PI3K   phosphatidylinositol 3-kinase 
PTK   tyrosine protein kinase 
TCA   trichloracetic acid 
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